Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
December 2025
in “
Zenodo (CERN European Organization for Nuclear Research)
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → 
Studysummary This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions. Our plain-language summary of this paper — not a Tressless recommendation.
The policy brief addresses post-drug syndromes (PDS) as a neglected category of adverse drug reactions, highlighting conditions like Post-Finasteride Syndrome and Post-SSRI Sexual Dysfunction. It critiques current pharmacovigilance systems for focusing on acute adverse events, thus overlooking long-term drug-induced harms. The document identifies systemic failures, such as assumptions of reversibility, limitations in reporting systems, and gaps in governance and education. It proposes recommendations to enhance drug safety oversight, including recognizing PDS in pharmacovigilance, developing longitudinal reporting mechanisms, and integrating persistent adverse effects into medical education. The brief aims to shift pharmacovigilance towards proactive, life-course–oriented safety surveillance to prevent enduring iatrogenic injury.
